ConductScience.org, home

Paper36848639

Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Wong RSM and 14 others. Blood Adv, 2023. Cited by 62 papers, by iCite.

Cite this record

ConductScience Library. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Papers, record 36848639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36848639

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
PubMed
Journal
Blood Adv
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
62
iCite
Relative citation ratio, by iCite
7.73
iCite
Revised in PubMed
2023-11-02
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wong RSMRaymond Siu Ming
2Navarro-Cabrera JRJuan Ramon
3Comia NSNarcisa Sonia
4Goh YTYeow Teehttps://orcid.org/0000-0002-7069-0997
5Idrobo HHenry
6Kongkabpan DDaolada
7Gómez-Almaguer DDavid
8Al-Adhami MMohammedhttps://orcid.org/0000-0003-2021-747X
9Ajayi TTemitayo
10Alvarenga PPaulo
11Savage JJessica
12Deschatelets PPascalhttps://orcid.org/0009-0001-0123-5528
13Francois CCedric
14Grossi FFederico
15Dumagay TTeresita

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hemoglobinuria, ParoxysmalMajor topic
Adult
Humans
Complement Inactivating Agents
Hemolysis
Antibodies, Monoclonal, Humanized
Hemoglobins
L-Lactate Dehydrogenase

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04085601A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNHDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137180495A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?Ther Adv Rare Dis2020https://conductscience.org/library/papers/37180495PubMed
231258525Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.Front Immunol2019https://conductscience.org/library/papers/31258525PubMed
333356783Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs.J Manag Care Spec Pharm2020https://conductscience.org/library/papers/33356783PubMed
437804344
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Ann Hematol2024https://conductscience.org/library/papers/37804344PubMed
530510080Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.Blood2019https://conductscience.org/library/papers/30510080PubMed
624456505European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies.Acta Oncol2014https://conductscience.org/library/papers/24456505PubMed
724488565Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.Haematologica2014https://conductscience.org/library/papers/24488565PubMed
816990386The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.N Engl J Med2006https://conductscience.org/library/papers/16990386PubMed
92478585Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.J Clin Invest1989https://conductscience.org/library/papers/2478585PubMed
1035869170Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.Ann Hematol2022https://conductscience.org/library/papers/35869170PubMed
1118055865Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.Blood2008https://conductscience.org/library/papers/18055865PubMed
128306954Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.EMBO J1994https://conductscience.org/library/papers/8306954PubMed
1333178408One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.Ther Adv Hematol2020https://conductscience.org/library/papers/33178408PubMed
1416051736Diagnosis and management of paroxysmal nocturnal hemoglobinuria.Blood2005https://conductscience.org/library/papers/16051736PubMed
1511900238Fatigue in cancer patients compared with fatigue in the general United States population.Cancer2002https://conductscience.org/library/papers/11900238PubMed
1622639982Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function.Br J Haematol2012https://conductscience.org/library/papers/22639982PubMed
1729246924The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source.Haematologica2018https://conductscience.org/library/papers/29246924PubMed
1834973099The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.Ann Hematol2022https://conductscience.org/library/papers/34973099PubMed
1919179465Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.Blood2009https://conductscience.org/library/papers/19179465PubMed
2034226670Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.Bone Marrow Transplant2021https://conductscience.org/library/papers/34226670PubMed

See all 26 referencesDownload CSV of references

Cited by41

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.

PMIDTitleJournalYearIn PapersSource
42597498Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration.Mol Ther Nucleic Acids2026https://conductscience.org/library/papers/42597498PubMed
42381976Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria.Drug Des Devel Ther2026https://conductscience.org/library/papers/42381976PubMed
42353312Mitochondria: The Crossroads of Complement Activation and Kidney Injury Progression.Int J Mol Sci2026https://conductscience.org/library/papers/42353312PubMed
42322093Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.Eur J Haematol2026https://conductscience.org/library/papers/42322093PubMed
42279078Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.J Clin Med2026https://conductscience.org/library/papers/42279078PubMed
42185224
Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes.
Eur J Haematol2026https://conductscience.org/library/papers/42185224PubMed
41961736New Anticomplement Drugs in Nephrology: Mechanism and Indication.Kidney Blood Press Res2026https://conductscience.org/library/papers/41961736PubMed
41809517Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease.J Blood Med2026https://conductscience.org/library/papers/41809517PubMed
41455944Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations.Cost Eff Resour Alloc2025https://conductscience.org/library/papers/41455944PubMed
41348037The varieties of therapeutic experience: navigating treatment options for patients with PNH.Hematology Am Soc Hematol Educ Program2025https://conductscience.org/library/papers/41348037PubMed
41268092Paroxysmal Nocturnal Hemoglobinuria in Pregnancy Treated With Pegcetacoplan: Case Report and Pharmacokinetic Analysis.EJHaem2025https://conductscience.org/library/papers/41268092PubMed
41255851Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders.J Blood Med2025https://conductscience.org/library/papers/41255851PubMed
41002734Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.Diseases2025https://conductscience.org/library/papers/41002734PubMed
40986193Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition.Drugs2025https://conductscience.org/library/papers/40986193PubMed
40777953The Onerous task of managing paroxysmal nocturnal hemoglobinuria in a Low resource setting: a case report. A hematologist's experience.Afr Health Sci2024https://conductscience.org/library/papers/40777953PubMed
40720060Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.Adv Ther2025https://conductscience.org/library/papers/40720060PubMed
40565360Complement System Inhibitors in Nephrology: An Update-Narrative Review.Int J Mol Sci2025https://conductscience.org/library/papers/40565360PubMed
40354320Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy.Blood Adv2025https://conductscience.org/library/papers/40354320PubMed
40276419Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report.Cureus2025https://conductscience.org/library/papers/40276419PubMed
40123793EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial.EJHaem2025https://conductscience.org/library/papers/40123793PubMed

See all 41 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
CD551604PubTator's text mininghttps://conductscience.org/library/genes/1604NCBI Gene
CD59966PubTator's text mininghttps://conductscience.org/library/genes/966NCBI Gene
PIGA5277PubTator's text mininghttps://conductscience.org/library/genes/5277NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PEGCETACOPLANCHEMBL4298211Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4298211

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36848639

GET https://conductscience.org/api/papers/v1/36848639/references?page=2